{"protocolSection": {"identificationModule": {"nctId": "NCT01252563", "orgStudyIdInfo": {"id": "A0531097"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "Amlodipine 10mg Drug Use Investigation", "officialTitle": "NORVASC10MG DRUG USE INVESTIGATION", "acronym": "ENTER10"}, "statusModule": {"statusVerifiedDate": "2021-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2012-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-12-01", "studyFirstSubmitQcDate": "2010-12-01", "studyFirstPostDateStruct": {"date": "2010-12-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-11-13", "resultsFirstSubmitQcDate": "2019-04-01", "resultsFirstPostDateStruct": {"date": "2019-04-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-01-26", "lastUpdatePostDateStruct": {"date": "2021-01-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "In this survey, to collect the safety and efficacy information in the subjects who have been treated with amlodipine 5mg at least 4 weeks in daily practice.", "detailedDescription": "All the subjects whom an investigator prescribes Amlodipine (Norvasc\u00ae) 10mg Tablet should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["ENTER10", "Hypertension", "Japanese", "Norvasc 10mg", "Post Marketing surveillance"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 14141, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Amlodipine 10mg Tablet", "description": "Subjects taking Amlodipine 10mg Tablet.", "interventionNames": ["Drug: Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine", "description": "Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.", "armGroupLabels": ["Amlodipine 10mg Tablet"], "otherNames": ["Norvasc"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Treatment Related Adverse Events", "description": "A treatment-related adverse event was any untoward medical occurrence attributed to Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day. Relatedness to Amlodipine Tablets or Amlodipine OD Tablets was assessed by the investigator and sponsor (Pfizer Japan Inc.).", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "The Achievement Rate to Ambulatory Blood Pressure Goal", "description": "The achievement rates to ambulatory blood pressure goal specified in the Japanese guidelines (JSH2009) were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)"}, {"measure": "Changes in Ambulatory Systolic Blood Pressure From Baseline", "description": "Changes in ambulatory systolic blood pressure (SBP) from baseline were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)"}, {"measure": "Changes in Ambulatory Diastolic Blood Pressure From Baseline", "description": "Changes in ambulatory diastolic blood pressure (DBP) from baseline were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)"}], "secondaryOutcomes": [{"measure": "Number of Participants With Adverse Events Listed in Japanese Package Insert", "description": "Adverse events refer to all events undesirable for participants that occur after the start of treatment with Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day, regardless of presence/absence of causal relationship with Amlodipine Tablets or Amlodipine OD Tablets (including clinically significant abnormal changes in laboratory test values).", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Treatment Related Adverse Events Unlisted in Japanese Package Insert", "description": "A treatment-related adverse event was any untoward medical occurrence attributed to Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day. Relatedness to Amlodipine Tablets or Amlodipine OD Tablets was assessed by the investigator and sponsor (Pfizer Japan Inc.).", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants With Treatment-Related Adverse Events: With/Without Complication(s)", "description": "To determine whether having complication(s) was a significant risk factor likely to affect the frequency of treatment-related adverse events. Complications included dyslipidemia, diabetes mellitus, metabolic syndrome, chronic kidney disease, angina pectoris, cerebrovascular disease, and myocardial infarction.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants With Treatment-Related Adverse Events: Male vs. Female", "description": "To determine whether gender was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Angina Pectoris)", "description": "To determine whether having angina pectoris as a complication was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Dyslipidaemia)", "description": "To determine whether having dyslipidaemia as a complication was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (Antihypertensive)", "description": "To determine whether receiving antihypertensive as a concomitant drug was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (ARB)", "description": "To determine whether receiving ARB as a concomitant drug was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Diabetes Mellitus)", "description": "To determine whether having diabetes mellitus as a complication was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Chronic Kidney Disease)", "description": "To determine whether having chronic kidney disease as a complication was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Myocardial Infarction)", "description": "To determine whether having myocardial infarction as a complication was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Metabolic Syndrome)", "description": "To determine whether having metabolic syndrome as a complication was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "Number of Participants Who Achieved the Target Blood Pressure: Ambulatory Systolic Blood Pressure", "description": "To determine whether ambulatory systolic blood pressure at baseline was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "timeFrame": "Last day of observation period (average of 14.76 weeks)"}, {"measure": "The Achievement Rate to Home Blood Pressure Goal", "description": "The achievement rates to home blood pressure goal specified in the Japanese guidelines (JSH2009) were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)"}, {"measure": "Changes in Home Systolic Blood Pressure From Baseline", "description": "Changes in home systolic blood pressure (SBP) from baseline were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)"}, {"measure": "Changes in Home Diastolic Blood Pressure From Baseline", "description": "Changes in home diastolic blood pressure (DBP) from baseline were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female subjects who have been treated with amlodipine 5mg at least 4 weeks\n* The subjects who had not achieved target BP\n\nExclusion Criteria:\n\n* Subjects who have been prescribed amlodipine (Norvasc\u00ae) 10mg Tablet before", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "The subjects who have been treated with amlodipine 5mg at least 4 weeks and had not achieved target BP.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0531097&StudyName=Amlodipine%2010mg%20Drug%20Use%20Investigation"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 14141 participants were registered in the study. Of the 14141 participants, 366 participants were excluded from the study because their case report forms were not collected, mainly due to the lack of cooperation from the investigators. Finally, 13775 participants were included in the study.", "groups": [{"id": "FG000", "title": "Amlodipine 10 mg Tablet", "description": "Participants taking Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13775"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13343"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "432"}]}], "dropWithdraws": [{"type": "Contract Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "41"}]}, {"type": "Centralized Registration Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "30"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "161"}]}, {"type": "No visit after first day of treatment", "reasons": [{"groupId": "FG000", "numSubjects": "194"}]}, {"type": "No drug administration", "reasons": [{"groupId": "FG000", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "A total of 13775 participants completed the survey. Of the 13775 participants, a total of 432 participants were excluded from the baseline analysis for the following reasons: no visit after first day of treatment, lost to follow up, contract deviation, centralized registration deviation and no drug administration.", "groups": [{"id": "BG000", "title": "Amlodipine 10 mg Tablet", "description": "Participants taking Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13343"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "5229"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "8114"}]}]}]}, {"title": "Sex/Gender, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5839"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7504"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Treatment Related Adverse Events", "description": "A treatment-related adverse event was any untoward medical occurrence attributed to Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day. Relatedness to Amlodipine Tablets or Amlodipine OD Tablets was assessed by the investigator and sponsor (Pfizer Japan Inc.).", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "Amlodipine 10 mg Tablet", "description": "Participants taking Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13343"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "208"}]}]}]}, {"type": "PRIMARY", "title": "The Achievement Rate to Ambulatory Blood Pressure Goal", "description": "The achievement rates to ambulatory blood pressure goal specified in the Japanese guidelines (JSH2009) were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "The Achievement Rate to Ambulatory Blood Pressure Goal", "description": "The achievement rates to ambulatory blood pressure goal specified in the Japanese guidelines (JSH2009) were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13124"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9655"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "35.1", "lowerLimit": "34.2", "upperLimit": "36.1"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9534"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "40.1", "lowerLimit": "39.1", "upperLimit": "41.0"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8958"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43.9", "lowerLimit": "42.8", "upperLimit": "44.9"}]}]}, {"title": "Last Day", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12987"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43.9", "lowerLimit": "43.0", "upperLimit": "44.7"}]}]}]}, {"type": "PRIMARY", "title": "Changes in Ambulatory Systolic Blood Pressure From Baseline", "description": "Changes in ambulatory systolic blood pressure (SBP) from baseline were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "Changes in Ambulatory SBP From Baseline", "description": "changes in ambulatory SBP from baseline at weeks 4, 8, and 12 as well as on the last day of the observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13124"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9637"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.8", "spread": "15.20"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9520"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.4", "spread": "15.90"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8948"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.9", "spread": "16.05"}]}]}, {"title": "Last Day", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12963"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.1", "spread": "16.31"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in ambulatory SBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 4", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in ambulatory SBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 8", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in ambulatory SBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 12", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in ambulatory SBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Last Day", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}]}, {"type": "PRIMARY", "title": "Changes in Ambulatory Diastolic Blood Pressure From Baseline", "description": "Changes in ambulatory diastolic blood pressure (DBP) from baseline were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "Changes in Ambulatory DBP From Baseline", "description": "changes in ambulatory DBP from baseline at weeks 4, 8, and 12 as well as on the last day of the observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13124"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9633"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.2", "spread": "10.47"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9514"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.1", "spread": "10.75"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8944"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.9", "spread": "11.03"}]}]}, {"title": "Last Day", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12958"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.0", "spread": "11.06"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in ambulatory DBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 4", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis.", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in ambulatory DBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 8", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in ambulatory DBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 12", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in ambulatory DBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Last Day", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events Listed in Japanese Package Insert", "description": "Adverse events refer to all events undesirable for participants that occur after the start of treatment with Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day, regardless of presence/absence of causal relationship with Amlodipine Tablets or Amlodipine OD Tablets (including clinically significant abnormal changes in laboratory test values).", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "Amlodipine 10 mg Tablet", "description": "Participants taking Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13343"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "566"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Related Adverse Events Unlisted in Japanese Package Insert", "description": "A treatment-related adverse event was any untoward medical occurrence attributed to Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day. Relatedness to Amlodipine Tablets or Amlodipine OD Tablets was assessed by the investigator and sponsor (Pfizer Japan Inc.).", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "Amlodipine 10 mg Tablet", "description": "Participants taking Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13343"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-Related Adverse Events: With/Without Complication(s)", "description": "To determine whether having complication(s) was a significant risk factor likely to affect the frequency of treatment-related adverse events. Complications included dyslipidemia, diabetes mellitus, metabolic syndrome, chronic kidney disease, angina pectoris, cerebrovascular disease, and myocardial infarction.", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With Complication(s)", "description": "Participants who had at least one complication and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}, {"id": "OG001", "title": "Without Complication(s)", "description": "Participants who had no complication and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9177"}, {"groupId": "OG001", "value": "4166"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Complication\". The null hypothesis was that there was no difference between participants with complication(s) and participants without complication in the frequency of treatment-related adverse events.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-Related Adverse Events: Male vs. Female", "description": "To determine whether gender was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "Male", "description": "Male participants who experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}, {"id": "OG001", "title": "Female", "description": "Female participants who experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7504"}, {"groupId": "OG001", "value": "5839"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87"}, {"groupId": "OG001", "value": "121"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Gender\". The null hypothesis was that there was no difference between male and female in the frequency of treatment-related adverse events.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Angina Pectoris)", "description": "To determine whether having angina pectoris as a complication was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With Angina Pectoris", "description": "Participants who had angina pectoris as a complication and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}, {"id": "OG001", "title": "Without Angina Pectoris", "description": "Participants who had no angina pectoris as a complication and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "872"}, {"groupId": "OG001", "value": "12471"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "187"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"angina pectoris\" as a complication. The null hypothesis was that there was no difference between participants with angina pectoris and participants without angina pectoris in the frequency of treatment-related adverse events.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.036", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Dyslipidaemia)", "description": "To determine whether having dyslipidaemia as a complication was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With Dyslipidaemia", "description": "Participants who had dyslipidaemia as a complication and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}, {"id": "OG001", "title": "Without Dyslipidaemia", "description": "Participants who had no dyslipidaemia as a complication and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5308"}, {"groupId": "OG001", "value": "8035"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "109"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"dyslipidaemia\" as a complication. The null hypothesis was that there was no difference between participants with dyslipidaemia and participants without dyslipidaemia in the frequency of treatment-related adverse events.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.020", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (Antihypertensive)", "description": "To determine whether receiving antihypertensive as a concomitant drug was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With Antihypertensive", "description": "Participants who received antihypertensive as a concomitant drug and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}, {"id": "OG001", "title": "Without Antihypertensive", "description": "Participants who received no antihypertensive as a concomitant drug and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7834"}, {"groupId": "OG001", "value": "5509"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "72"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"antihypertensive\" as a concomitant drug. The null hypothesis was that there was no difference between participants receiving antihypertensive and participants receiving no antihypertensive in the frequency of treatment-related adverse events.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.049", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (ARB)", "description": "To determine whether receiving ARB as a concomitant drug was a significant risk factor likely to affect the frequency of treatment-related adverse events.", "populationDescription": "The safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With ARB", "description": "Participants who received ARB as a concomitant drug and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}, {"id": "OG001", "title": "Without ARB", "description": "Participants who received no ARB as a concomitant drug and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6641"}, {"groupId": "OG001", "value": "6702"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "90"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"ARB\" as a concomitant drug. The null hypothesis was that there was no difference between participants receiving ARB and participants receiving no ARB in the frequency of treatment-related adverse events.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.043", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Diabetes Mellitus)", "description": "To determine whether having diabetes mellitus as a complication was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With Diabetes Mellitus", "description": "Participants with diabetes mellitus as a complication who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}, {"id": "OG001", "title": "Without Diabetes Mellitus", "description": "Participants without diabetes mellitus as a complication who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2247"}, {"groupId": "OG001", "value": "7004"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "892"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"diabetes mellitus\" as a complication. The null hypothesis was that there was no difference between participants with diabetes mellitus and participants without diabetes mellitus in the efficacy.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Chronic Kidney Disease)", "description": "To determine whether having chronic kidney disease as a complication was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With Chronic Kidney Disease", "description": "Participants with chronic kidney disease as a complication who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}, {"id": "OG001", "title": "Without Chronic Kidney Disease", "description": "Participants without chronic kidney disease as a complication who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1034"}, {"groupId": "OG001", "value": "8217"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "920"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"chronic kidney disease\" as a complication. The null hypothesis was that there was no difference between participants with chronic kidney disease and participants without chronic kidney disease in the efficacy.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Myocardial Infarction)", "description": "To determine whether having myocardial infarction as a complication was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With Myocardial Infarction", "description": "Participants with myocardial infarction as a complication who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}, {"id": "OG001", "title": "Without Myocardial Infarction", "description": "Participants without myocardial infarction as a complication who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "9196"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "943"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"myocardial infarction\" as a complication. The null hypothesis was that there was no difference between participants with myocardial infarction and participants without myocardial infarction in the efficacy.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.039", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Metabolic Syndrome)", "description": "To determine whether having metabolic syndrome as a complication was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "With Metabolic Syndrome", "description": "Participants with metabolic syndrome as a complication who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}, {"id": "OG001", "title": "Without Metabolic Syndrome", "description": "Participants without metabolic syndrome as a complication who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1716"}, {"groupId": "OG001", "value": "7535"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "852"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"metabolic syndrome\" as a complication. The null hypothesis was that there was no difference between participants with metabolic syndrome and participants without metabolic syndrome in the efficacy.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants Who Achieved the Target Blood Pressure: Ambulatory Systolic Blood Pressure", "description": "To determine whether ambulatory systolic blood pressure at baseline was a significant risk factor likely to affect the efficacy. The achievement rates to the target blood pressure specified in the Japanese guidelines (JSH2009) were calculated on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "<120 mmHg at Baseline", "description": "Participants with ambulatory SBP of below 120 mmHg at baseline who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}, {"id": "OG001", "title": "120 to 140 mmHg at Baseline", "description": "Participants with ambulatory SBP of 120 to 140 mmHg at baseline who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}, {"id": "OG002", "title": "140 to 160 mmHg at Baseline", "description": "Participants with ambulatory SBP of 140 to 160 mmHg at baseline who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}, {"id": "OG003", "title": "160 to 180 mmHg at Baseline", "description": "Participants with ambulatory SBP of 160 to 180 mmHg at baseline who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}, {"id": "OG004", "title": ">= 180 mmHg at Baseline", "description": "Participants with ambulatory SBP of 180 mmHg or above at baseline who received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "863"}, {"groupId": "OG002", "value": "4675"}, {"groupId": "OG003", "value": "2808"}, {"groupId": "OG004", "value": "757"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "171"}, {"groupId": "OG002", "value": "543"}, {"groupId": "OG003", "value": "182"}, {"groupId": "OG004", "value": "26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003", "OG004"], "groupDescription": "The risk factor tested was \"ambulatory SBP at baseline\". The null hypothesis was that there was no association between ambulatory SBP at baseline and the number of participants who achieved the target blood pressure specified in the guidelines.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "The Achievement Rate to Home Blood Pressure Goal", "description": "The achievement rates to home blood pressure goal specified in the Japanese guidelines (JSH2009) were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "The Achievement Rate to Home Blood Pressure Goal", "description": "The achievement rates to home blood pressure goal specified in the Japanese guidelines (JSH2009) were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13124"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2841"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.2", "lowerLimit": "19.7", "upperLimit": "22.8"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2675"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27.9", "lowerLimit": "26.2", "upperLimit": "29.6"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2543"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "32.2", "lowerLimit": "30.4", "upperLimit": "34.1"}]}]}, {"title": "Last Day", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4265"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "31.3", "lowerLimit": "29.9", "upperLimit": "32.7"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Home Systolic Blood Pressure From Baseline", "description": "Changes in home systolic blood pressure (SBP) from baseline were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "Changes in Home SBP From Baseline", "description": "Mean changes in home SBP from baseline at weeks 4, 8, and 12 as well as on the last day of the observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13124"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2427"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.7", "spread": "13.34"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2302"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.0", "spread": "13.80"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2183"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.9", "spread": "14.38"}]}]}, {"title": "Last Day", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3494"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.6", "spread": "14.27"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in home SBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 4", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in home SBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 8", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in home SBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 12", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean change in home SBP from the baseline was equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Last Day", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}]}, {"type": "SECONDARY", "title": "Changes in Home Diastolic Blood Pressure From Baseline", "description": "Changes in home diastolic blood pressure (DBP) from baseline were calculated at weeks 4, 8, and 12 as well as on the last day of the observation period.", "populationDescription": "The efficacy analysis population consisted of the participants, among the safety analysis population, who had their SBP/DBP measurement prior to the start of treatment and at least one post-baseline SBP/DBP measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "4, 8, 12 weeks and last day of observation period (average of 14.76 weeks)", "groups": [{"id": "OG000", "title": "Changes in Home Diastolic Blood Pressure From Baseline", "description": "Mean changes in home DBP from baseline at weeks 4, 8, and 12 as well as on the last day of the observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13124"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2332"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.3", "spread": "9.21"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2209"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.5", "spread": "9.46"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.4", "spread": "10.07"}]}]}, {"title": "Last Day", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3330"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.4", "spread": "9.82"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean changes in home DBP from the baseline are equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 4", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean changes in home DBP from the baseline are equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 8", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean changes in home DBP from the baseline are equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Week 12", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that the mean changes in home DBP from the baseline are equal to 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Last Day", "statisticalMethod": "t-test, 1 sided", "statisticalComment": "A one-sided paired t-test was performed to test the hypothesis."}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.1", "description": "The frequency of adverse events during the study.", "eventGroups": [{"id": "EG000", "title": "Amlodipine 10 mg Tablet", "description": "Participants taking Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert.", "seriousNumAffected": 78, "seriousNumAtRisk": 13343, "otherNumAffected": 250, "otherNumAtRisk": 13343}], "seriousEvents": [{"term": "Enteritis infectious", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Meningitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 13343}]}, {"term": "Hepatic neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Uterine cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Oesophageal carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Intracranial haemangioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Marasmus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 13343}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 13343}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 13343}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "VIIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 13343}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 13343}]}, {"term": "Ruptured cerebral aneurysm", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Prinzmetal angina", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 13343}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 13343}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 13343}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Aortic aneurysm rupture", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 13343}]}, {"term": "Pulmonary congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Emphysema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Ascites", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Aphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Hepatic failure", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Photosensitivity reaction", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Rheumatoid arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Osteoporosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Nephrotic syndrome", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Azotaemia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Renal disorder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Renal cyst haemorrhage", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 13343}]}, {"term": "Pollakiuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Renal failure chronic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Generalised oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Traumatic lung injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 13343}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 17, "numAtRisk": 13343}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 22, "numAtRisk": 13343}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 14, "numAtRisk": 13343}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 45, "numAffected": 45, "numAtRisk": 13343}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 14, "numAtRisk": 13343}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 15, "numAtRisk": 13343}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 16, "numAtRisk": 13343}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 14, "numAtRisk": 13343}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 85, "numAffected": 85, "numAtRisk": 13343}]}, {"term": "Blood pressure decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 23, "numAtRisk": 13343}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}